Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Blood Product Support

Off-label use of recombinant factor VIIa in patients following bone marrow transplantation

Abstract

Recombinant factor VIIa (rFVIIa, NovoSeven) is FDA-approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A growing literature suggests that there may be expanded indications for the use of NovoSeven in patients with significant bleeding who do not have a known factor deficiency. Severe bleeding refractory to standard hematologic or hemostatic support is common in patients undergoing bone marrow transplantation (BMT). We review our experience with rFVIIa in three patients (8 years 8 months to 19 years, median 13 years) treated for pulmonary hemorrhage (n = 1), hemorrhagic cystitis (n = 3), and gastrointestinal bleeding (n = 2). Boluses of 90–270 μg/kg rVIIa with subsequent doses of 90 μg/kg every 4–24 h for 3–14 days were given, concurrent with maintaining platelet counts >50 000/mm3. Transient clinical responses in gross hematuria (two patients) and in pulmonary hemorrhage were noted within several days of starting rFVIIa, but bleeding in a new site in two patients and renewed bleeding of the initial site in the third resulted in discontinuation of the drug. No toxicity or adverse events were observed while the patients were on rFVIIa treatment. Because of the substantial cost of this product, the lack of adequate monitoring methodology, and the variability of current dose and dosing intervals, large randomized studies are needed before definitive off-label use in the setting of BMT can be recommended. Bone Marrow Transplantation (2001) 28, 405–407.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Mariani G, Testa MG, Paolantonio T et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies Vox Sanguinis 1999 77: 131–136

    Article  CAS  Google Scholar 

  2. Monroe DM, Hoffman M, Oliver JA, Roberts HR . Platelet activity of high-dose factor VIIa is independent of tissue factor Br J Haematol 1997 99: 542–547

    Article  CAS  Google Scholar 

  3. Hedner U . Recombinant activated factor VII as a universal haemostatic agent Blood Coag Fibrin 1998 9: (Suppl. 1) S147–S152

    CAS  Google Scholar 

  4. White B, Martin M, Kelleher S et al. Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency Br J Haematol 1999 106: 254–255

    Article  CAS  Google Scholar 

  5. Novo Nordisk Investigator's Brochure. Recombinant Coagulation Factor VIIa 1999 pp 42–47

  6. Poon M-C, Katsarou O, Huth-Kuehne A et al. Recombinant Factor VIIa in congenital platelet bleeding disorders Proc Am Soc Hematol 2000 96: 256a

    Google Scholar 

  7. Chuansumrit A, Chantarojanasiri T, Isarangkura P et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation Blood Coag Fibrinol 2000 11: (Suppl. 1) S101–S105

    Article  CAS  Google Scholar 

  8. Al Douri M, Shafi T, Al Khudairi D et al. Effect of theadministration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery Blood Coag Fibrinol 2000 11: (Suppl. 1) S121–S127

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blatt, J., Gold, S., Wiley, J. et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 28, 405–407 (2001). https://doi.org/10.1038/sj.bmt.1703157

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703157

Keywords

This article is cited by

Search

Quick links